Literature DB >> 7805650

Glucocorticoid action and the clinical features of Cushing's syndrome.

J A Yanovski1, G B Cutler.   

Abstract

Glucocorticoids mainly act through binding to cytosolic receptors that translocate to the nucleus after ligand binding, and dimerize to affect gene transcription in multiple fashions. The liganded receptors may interact with DNA at specific glucocorticoid responsive-elements, may physically hinder the ability of other transcription-regulating proteins to interact with their own DNA response-elements, and may form intranuclear complexes with the transcription factor c-jun, thus changing the number of c-jun/c-fos heterodimers that bind at AP-1 sites. By these, and perhaps other, mechanisms, physiologic concentrations of glucocorticoids regulate normal tissue metabolism, and supraphysiologic concentrations cause Cushing's syndrome. Cushing's syndrome leaves virtually no body tissue untouched. Left untreated, it results in progressive adiposity, myopathy, dermopathy (atrophy, stria, purpura, and hirsutism), psychopathy, glucose intolerance, hypercholesterolemia, hypertension, atherosclerosis, immunosuppression, and, ultimately, death. The physiology underlying each of these effects of hypercortisolism has been reviewed. The differences in the presentation of Cushing's syndrome in children and adults have also been discussed. The goal of the clinician must be to identify individuals with Cushing's syndrome as early in the course of the disease as possible so as to avoid the devastating complications that result from prolonged hypercortisolism. In patients for whom screening tests are equivocal, or only intermittently elevated, it may be necessary to re-evaluate the patient over time to establish that the patient has hypercortisolism. Some clinical guidelines for which patients to screen for hypercortisolism have been presented. Once hypercortisolism is established, patients with mild hypercortisolism (urine free cortisol less than four-fold above the upper limit of normal) should undergo tests to differentiate true Cushing's syndrome from a pseudo-Cushing state.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7805650

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  17 in total

1.  Bipolar affective disorder, stress fractures, fungal dermopathy and 'tree frog fingers'.

Authors:  M Reuber; K Misch; V Patel
Journal:  Postgrad Med J       Date:  1998-02       Impact factor: 2.401

2.  The modulation of glucocorticoid receptor content by 3-O-methyl-D-glucose transport in human mononuclear leukocyte in obesity.

Authors:  M Güven; H Hatemi; E Taşan; Y Altuntaş; T Ulutin; V Tezcan; G Kanigür-Sultuybek
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

3.  Severe respiratory failure secondary to Cushing's myopathy.

Authors:  C Blanco; M Marazuela; J Flores; J Alvarez
Journal:  J Endocrinol Invest       Date:  2001-09       Impact factor: 4.256

4.  Severe Hypokalaemia, Hypertension, and Intestinal Perforation in Ectopic Adrenocorticotropic Hormone Syndrome.

Authors:  Tezcan Kaya; Cengiz Karacaer; Seyyid Bilal Açikgöz; Yusuf Aydemir; Ali Tamer
Journal:  J Clin Diagn Res       Date:  2016-01-01

Review 5.  Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management.

Authors:  Alan Sacerdote; Karolina Weiss; Tri Tran; Begum Rokeya Noor; Samy I McFarlane
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

6.  Predictive factors for neurocognitive function and Quality of Life after surgical treatment for Cushing's disease and acromegaly.

Authors:  T Psaras; M Milian; V Hattermann; B E Will; M Tatagiba; J Honegger
Journal:  J Endocrinol Invest       Date:  2010-11-08       Impact factor: 4.256

7.  Clinical laboratory findings and results of therapy in 55 patients with Cushing's syndrome.

Authors:  C Erem; E Algün; N Ozbey; A Azezli; F Aral; Y Orhan; S Molvalilar; E Sencer
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

8.  Screening for Cushing's syndrome in obese patients.

Authors:  Ozay Tiryakioglu; Serdal Ugurlu; Serap Yalin; Sibel Yirmibescik; Erkan Caglar; Demet Ozgil Yetkin; Pinar Kadioglu
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

9.  Psychosocial morbidity in Cushing disease: a study from India.

Authors:  Surendra Kumar Mattoo; Anil Kumar Bhansali; Nitin Gupta; Sandeep Grover; Rama Malhotra
Journal:  Endocrine       Date:  2009-04-09       Impact factor: 3.633

10.  Cushing's syndrome patient who exhibited congestive heart failure.

Authors:  L Petramala; P Battisti; G Lauri; L Palleschi; D Cotesta; M Iorio; G De Toma; S Sciomer; C Letizia
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.